Fig. 2: Complete responses to DNX-2401 and pembrolizumab.
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
a, Axial T1-weighted MR (top row) and FLAIR images (bottom row) obtained at baseline, 3 months, 6 months, 12 months and 38 months after infusion of DNX-2401 for one complete responder. b, The change of tumor size over time in each patient with a complete response. Dotted black line represents no change relative to baseline. Dashed red line represents the threshold for response according to the mRANO criteria. Both patients showed response to treatment at 3 months after DNX-2401 infusion, with complete response by 15–18 months.
